Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.67 |
| ▸ | ACE | P12821 | 6/20 | 0.65 |
| ▸ | CPA1 | P15085 | 6/20 | 0.65 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.65 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP7 | P09237 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31145898 | 1.00 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL23361048 | 1.00 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL31390236 | 1.00 | MME (0.67) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL12864507 | 0.88 | MME (0.69) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL8510053 | 0.88 | MME (0.69) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL8510050 | 0.88 | MME (0.69) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL10425350 | 0.87 | MME (0.67) | MMEACECPA1ACE2 | |
| SCHEMBL4572624 | 0.87 | MME (0.67) | MMEACECPA1ACE2 | |
| SCHEMBL24821176 | 0.87 | MME (0.67) | MMEACECPA1ACE2 | |
| SCHEMBL31390164 | 0.87 | MME (0.63) | MMEACECPA1ACE2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116879431-A | Alzheimer disease marker set and screening method and application thereof | 复旦大学 | 2023-10-13 | — | — | CN | claimed |
| CN-115524414-A | Marker, kit, method, device, computer device and storage medium for evaluating fertility of spermatozoa | 中信湘雅生殖与遗传专科医院有限公司 | 2022-12-27 | — | — | CN | claimed |
| EP-0804181-A4 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES INC (US) | 2005-02-02 | — | — | EP | claimed |
| EP-0804181-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | Cellular Sciences, Inc. (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1997010818-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES, INC. (US) | 1997-03-27 | — | — | WO | claimed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| CN-119985765-A | Method for simultaneously detecting 5 biological sample metabolites based on mass spectrum | 北京斯凯奥生物医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119242482-A | Lactobacillus rhamnosus JMB235, fermentation product and application thereof | 上海自然堂集团有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119212974-A | Combination lactic acid and ketoesters for medical and nutritional use | 奥胡斯大学 | 2024-12-27 | — | — | CN | disclosed |
| US-20240335409-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| US-20240122888-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240122884-A1 | SYSTEMS AND METHODS FOR DELIVERY OF N-LACTOYL-PHENYLALANINE AND OTHER N-LACTOYL-AMINO ACIDS | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2021094341-A1 | CELL CULTURE MEDIA | MERCK PATENT GMBH (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-0804181-A4 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6482856-B1 | Method and composition for treating mammalian disease caused by inflammatory response | CELLULAR SCIENCES, INC. | 2002-11-19 | — | — | US | disclosed |
| US-5952384-A | CONTACTING THE MAMMALIAN CELL WITH AN INFLAMMATORY MEDIATOR SELECTED FROM THE GROUP CONSISTS OF PYRUVATE AND PYRUVATE PRECURSOR CAPABLE OF REDUCING UNDESIRED INFLAMMATORY RESPONSE AND IS ANTIOXIDANT | CELLULAR SCIENCES, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5939459-A | CONTACTING WITH AN INFLAMMATORY MEDIATOR SELECTED FROM THE GROUP CONSISTING OF PYRUVATE AND A PYRUVATE PRECURSOR AND IS PRESENT IN AN AMOUNT CAPABLE OF REDUCING THE UNDESIRED INFLAMMATORY RESPONSE AND IS AN ANTIOXIDANT | CELLULAR SCIENCES INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5798388-A | ANTIOXIDANT, ANTIASTHMA, ADMINISTERING PYRUVATE WITHOUT ALBUTEROL | CELLULAR SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| EP-0804181-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | Cellular Sciences, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997010818-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES, INC. (US) | 1997-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240122884-A1 | SYSTEMS AND METHODS FOR DELIVERY OF N-LACTOYL-PHENYLALANINE AND OTHER N-LACTOYL-AMINO ACIDS | TYR, LANCL2, LRAT | MME 899/4885ACE 2349/4885CPA1 2305/4885 |
| US-20240122888-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | TYR, LANCL2, LRAT | MME 1735/4885ACE 2705/4885CPA1 2444/4885 |
| US-20240335409-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | TYR, LANCL2, LRAT | MME 1735/4885ACE 2705/4885CPA1 2444/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | MME 404/4885ACE 621/4885CPA1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.